Pmh28 a Cost-Effectiveness Analysis of Escitalopram and Sertraline in the Treatment of Major Depressive Disorder

Escitalopram ahead of the rest in MDD

“…1 As there are numerous SSRIs available on the treatment failure was assumed to be $US8141, when market, analyses comparing the cost effectiveness of this cost was decreased to $US5000, the cost/QALY these products, from a US managed care organisation gained was $US1993 and $US2808 for escitalopram and perspective, is needed, the research group continues. It was found effectiveness analyses between commonly-used that the model was most sensitive to the cost of products", according to a group of researchers from the treatment failure.…”